Gefitinib in recurrent non-small-cell lung cancer: An IDEAL trial?

被引：31

作者：

Johnson, DH ^{[1
]}

Arteaga, CL ^{[1
]}

机构：

[1] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Comprehens Canc Ctr, Div Hematol & Oncol, Nashville, TN 37212 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2003年 / 21卷 / 12期

关键词：

D O I：

10.1200/JCO.2003.04.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2227 / 2229

页数：3

共 33 条

[1] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].

Baselga, J ;

Rischin, D ;

Ranson, M ;

Calvert, H ;

Raymond, E ;

Kieback, DG ;

Kaye, SB ;

Gianni, L ;

Harris, A ;

Bjork, T ;

Averbuch, SD ;

Feyereislova, A ;

Swaisland, H ;

Rojo, F ;

Albanell, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302

[2] Influence of unrecognized molecular heterogeneity on randomized clinical trials [J].

Betensky, RA ;

Louis, DN ;

Cairncross, JG .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (10) :2495-2499

[3]

BIANCO R, IN PRESS ONCOGENE

[4]

Brabender J, 2001, CLIN CANCER RES, V7, P1850

[5] Employment of the epidermal growth factor receptor in growth factor-independent signaling pathways [J].

Carpenter, G .

JOURNAL OF CELL BIOLOGY, 1999, 146 (04) :697-702

[6]

Chakravarti A, 2002, CANCER RES, V62, P200

[7]

COHEN S, 1962, J BIOL CHEM, V237, P1555

[8] EPIDERMAL GROWTH-FACTOR RECEPTOR (EGFR) EXPRESSION IN NONSMALL CELL LUNG CARCINOMAS CORRELATES WITH METASTATIC INVOLVEMENT OF HILAR AND MEDIASTINAL LYMPH-NODES IN THE SQUAMOUS SUBTYPE [J].

FONTANINI, G ;

VIGNATI, S ;

BIGINI, D ;

MUSSI, A ;

LUCCHI, H ;

ANGELETTI, CA ;

PINGITORE, R ;

PEPE, S ;

BASOLO, F ;

BEVILACQUA, G .

EUROPEAN JOURNAL OF CANCER, 1995, 31A (02) :178-183

[9] Epidermal growth factor receptor family in lung cancer and premalignancy [J].

Franklin, WA ;

Veve, R ;

Hirsch, FR ;

Helfrich, BA ;

Bunn, PA .

SEMINARS IN ONCOLOGY, 2002, 29 (01) :3-14

[10] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].

Fukuoka, M ;

Yano, S ;

Giaccone, G ;

Tamura, T ;

Nakagawa, K ;

Douillard, JY ;

Nishiwaki, Y ;

Vansteenkiste, J ;

Kudoh, S ;

Rischin, D ;

Eek, R ;

Horai, T ;

Noda, K ;

Takata, I ;

Smit, E ;

Averbuch, S ;

Macleod, A ;

Feyereislova, A ;

Dong, RP ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246

← 1 2 3 4 →